JP2015524414A - Ｉｇｆ１ｒおよびｐｉ３ｋに対する阻害剤の併用治療 - Google Patents

Ｉｇｆ１ｒおよびｐｉ３ｋに対する阻害剤の併用治療 Download PDF

Info

Publication number
JP2015524414A
JP2015524414A JP2015523289A JP2015523289A JP2015524414A JP 2015524414 A JP2015524414 A JP 2015524414A JP 2015523289 A JP2015523289 A JP 2015523289A JP 2015523289 A JP2015523289 A JP 2015523289A JP 2015524414 A JP2015524414 A JP 2015524414A
Authority
JP
Japan
Prior art keywords
cancer
antibody
compound
inhibitor
igf1r
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015523289A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524414A5 (https=
Inventor
シジョン・フアン
マルテ・ペータース
カール・マリア・シューマッハー
ジュ・アレクサンダー・カオ
ジェニファー・ロレイン・ガンサート
デイヴィッド・ドン・ウン・チャン
Original Assignee
ノバルティス アーゲー
ノバルティス アーゲー
アムゲン・インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー, ノバルティス アーゲー, アムゲン・インコーポレーテッド filed Critical ノバルティス アーゲー
Publication of JP2015524414A publication Critical patent/JP2015524414A/ja
Publication of JP2015524414A5 publication Critical patent/JP2015524414A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2015523289A 2012-07-20 2013-07-19 Ｉｇｆ１ｒおよびｐｉ３ｋに対する阻害剤の併用治療 Pending JP2015524414A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261673809P 2012-07-20 2012-07-20
US61/673,809 2012-07-20
US201361759490P 2013-02-01 2013-02-01
US61/759,490 2013-02-01
PCT/US2013/051345 WO2014015280A1 (en) 2012-07-20 2013-07-19 Combination therapy of inhibitors for igf1 r and pi3k

Publications (2)

Publication Number Publication Date
JP2015524414A true JP2015524414A (ja) 2015-08-24
JP2015524414A5 JP2015524414A5 (https=) 2016-09-08

Family

ID=48875809

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015523289A Pending JP2015524414A (ja) 2012-07-20 2013-07-19 Ｉｇｆ１ｒおよびｐｉ３ｋに対する阻害剤の併用治療

Country Status (11)

Country Link
US (1) US8980259B2 (https=)
EP (1) EP2875050A1 (https=)
JP (1) JP2015524414A (https=)
KR (1) KR20150041783A (https=)
CN (1) CN104822703A (https=)
AU (1) AU2013292298A1 (https=)
BR (1) BR112015001212A2 (https=)
CA (1) CA2879219A1 (https=)
MX (1) MX2015000746A (https=)
RU (1) RU2015105786A (https=)
WO (1) WO2014015280A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2014011843A (es) * 2012-03-30 2014-12-10 Novartis Ag Compuestos para usarse en el tratamiento de neuroblastoma, sarcoma de ewing o rabdomiosarcoma.
CN106061505A (zh) * 2014-02-11 2016-10-26 诺华股份有限公司 用于治疗癌症的含pi3k抑制剂的药物组合
CN107250108B (zh) * 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合
US10722517B2 (en) 2015-05-08 2020-07-28 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of glioma
CN107573416A (zh) * 2016-06-30 2018-01-12 中国科学院深圳先进技术研究院 抗igf1r和cd3特异性双靶向抗体、含该双靶向抗体表达盒的微环dna及应用
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN113512116B (zh) * 2020-04-10 2022-09-20 苏州普乐康医药科技有限公司 一种抗igf-1r抗体及其应用
CN116925023B (zh) * 2023-07-18 2025-11-21 江苏桐孚高新材料有限公司 2-全氟烷基-4h-吡喃-4-酮衍生物的改进合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
JP2008525034A (ja) * 2004-12-22 2008-07-17 アムジェン インコーポレイテッド 抗ｉｇｆ−１受容体抗体に関する組成物および方法
JP2012502080A (ja) * 2008-09-10 2012-01-26 ノバルティス アーゲー 有機化合物

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
FR2714383B1 (fr) 1993-12-29 1996-02-09 Centre Nat Rech Scient Contrôle de l'expression de gènes.
US7020563B1 (en) 1997-11-27 2006-03-28 Commonwealth Scientific And Industrial Research Organisation Method of designing agonists and antagonists to IGF receptor
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US20030236190A1 (en) 1998-09-02 2003-12-25 Renuka Pillutla Isulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
EP1006184A1 (en) 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US6608108B2 (en) 1999-10-15 2003-08-19 Johns Hopkins University Method for treatment of tumors using nordihydroguaiaretic acid derivatives
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
WO2002072780A2 (en) 2001-03-14 2002-09-19 Genentech, Inc. Igf antagonist peptides
SE0104140D0 (sv) 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
SI1461359T1 (sl) 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
US7241444B2 (en) 2002-01-18 2007-07-10 Pierre Fabre Medicament Anti-IGF-IR antibodies and uses thereof
EP1432724A4 (en) 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
EP1506286B1 (en) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Neutralizing human anti-igfr antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
AR046071A1 (es) 2003-07-10 2005-11-23 Hoffmann La Roche Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos
UA83509C2 (en) 2003-10-15 2008-07-25 Оси Фармасьютикалз, Инк. Imidazopyrazines as tyrosine kinase inhibitors
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
WO2005082415A2 (en) 2004-02-25 2005-09-09 Dana Farber Cancer Institute, Inc. Inhibitors of insulin-like growth factor receptor-1 for inhibiting tumor cell growth
EP1732898B1 (en) 2004-03-12 2008-01-23 Analytecon S.A. Tetrahydroisoquinoline- and tetrahydrobenzazepine derivatives as igf-1r inhibitors
EP2168968B1 (en) 2004-04-02 2017-08-23 OSI Pharmaceuticals, LLC 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
JP2008503239A (ja) 2004-06-21 2008-02-07 エクセリクシス， インク． ＩＧＦ経路のモディファイヤーとしてのＡＣＡＣｓおよび使用方法
TW200613306A (en) 2004-07-20 2006-05-01 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
JP2008508358A (ja) 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
GB0426154D0 (en) 2004-11-29 2004-12-29 European Molecular Biology Lab Embl IGF-1 novel peptides
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
WO2007004060A2 (en) 2005-05-05 2007-01-11 Valorisation Hsj, Societe En Commandite Cytokine receptor modulators and uses thereof
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
WO2007000328A1 (en) 2005-06-27 2007-01-04 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Antibodies that bind to an epitope on insulin-like growth factor 1 receptor and uses thereof
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AU2006288847A1 (en) 2005-09-09 2007-03-15 Analytecon Sa Isoquinolines derivatives as IGF-1R inhibitors
ATE505457T1 (de) 2005-09-09 2011-04-15 Analytecon Sa Isochinoline als igf-1r-inhibitoren
WO2007031745A1 (en) 2005-09-16 2007-03-22 Astrazeneca Ab Pyrimidine derivatives for the inhibition of igf-ir tyrosine kinase activity
WO2007095113A2 (en) 2006-02-10 2007-08-23 Massachusetts Institute Of Technology Cpg15 and cpg15-2 compounds and inhibitors as insulin receptor and insulin-like growth factor receptor agonists and antagonists
WO2007099166A1 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Pyrazolo-pyridine derivatives active as kinase inhibitors
WO2007099171A2 (en) 2006-03-03 2007-09-07 Nerviano Medical Sciences S.R.L. Bicyclo-pyrazoles active as kinase inhibitors
AU2007245164A1 (en) 2006-03-28 2007-11-08 Biogen Idec Ma Inc. Anti-IGF-IR antibodies and uses thereof
MY150697A (en) * 2007-04-10 2014-02-28 Exelixis Inc Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008525034A (ja) * 2004-12-22 2008-07-17 アムジェン インコーポレイテッド 抗ｉｇｆ−１受容体抗体に関する組成物および方法
WO2008079849A2 (en) * 2006-12-22 2008-07-03 Genentech, Inc. Antibodies to insulin-like growth factor receptor
JP2012502080A (ja) * 2008-09-10 2012-01-26 ノバルティス アーゲー 有機化合物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JEROEN C. VERHEIJEN: "PHOSPHATIDYLINOSITOL 3-KINASE (PI3K) INHIBITORS AS ANTICANCER DRUGS", DRUGS OF THE FUTURE, vol. V32 N6, JPN5015008512, 1 January 2007 (2007-01-01), pages 537 - 547, ISSN: 0003712214 *
SAMUELS YARDENA: "ONCOGENIC PI3K AND ITS ROLE IN CANCER", CURRENT OPINION IN ONCOLOGY, vol. V18 N1, JPN5015008514, 1 January 2006 (2006-01-01), US, pages 77 - 82, ISSN: 0003712216 *
WEE SUSAN: "CLASS IA PHOSPHOINOSITIDE 3-KINASE ISOFORMS AND HUMAN TUMORIGENESIS: 以下備考", CURRENT OPINION IN ONCOLOGY, vol. V20 N1, JPN5015008513, 1 January 2008 (2008-01-01), US, pages 77 - 82, ISSN: 0003712215 *

Also Published As

Publication number Publication date
RU2015105786A (ru) 2016-09-10
BR112015001212A2 (pt) 2017-08-01
EP2875050A1 (en) 2015-05-27
KR20150041783A (ko) 2015-04-17
CN104822703A (zh) 2015-08-05
AU2013292298A1 (en) 2015-02-05
CA2879219A1 (en) 2014-01-23
US20140023661A1 (en) 2014-01-23
US8980259B2 (en) 2015-03-17
WO2014015280A1 (en) 2014-01-23
MX2015000746A (es) 2015-09-10

Similar Documents

Publication Publication Date Title
US8980259B2 (en) Combination therapy
JP7503887B2 (ja) がんを監視及び治療するための方法
JP2022115924A (ja) グロボシリーズの抗原を介した免疫活性化又は免疫調節によるがん免疫療法
US20180346586A1 (en) Methods of treating cancer using anti-ox40 antibodies
KR102088469B1 (ko) Mek 억제제 및 igf1r 억제제의 병용 요법
JP2018518483A (ja) 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
US20240424092A1 (en) Methods for treatment of cancer with an anti-tigit antagonist antibody
KR102934775B1 (ko) Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
US20240252632A1 (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
US20230398229A1 (en) Antibody drug conjugates comprising sting agonists, combinations and methods of use
CA2757730A1 (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific inhibitors
JP2023551432A (ja) グロボ系列抗原による免疫モジュレーションによる活動性がん免疫療法
JP7834711B2 (ja) Ｂ細胞悪性腫瘍の治療
WO2025040080A1 (en) Treatment of esophageal cancer with anti-lag3, anti-pd-1 and chemotherapy
AU2021320130B2 (en) Treatment of CLL
TW202342527A (zh) 鱗狀非小細胞肺癌之治療
HK40110052A (zh) 用於治疗癌症的方法和组合物
JP2025511333A (ja) 胃がんの治療
HK40119150A (zh) 用於治疗癌症的方法和组合物
HK40053012A (en) Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160715

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160715

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180105